NCT04658004View on ClinicalTrials.gov

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

January 15, 2024

Study Completion Date

January 15, 2027

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

NKG2D CAR T-cells

Each subject receive NKG2D CAR T-cells by intravenous infusion

Trial Locations (1)

310003

The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER